Leonhardt Ventures Technology Showcase @ JP Morgan Healthcare Conference

Stem Cell Technologies Including First Stem Cell Bra, Innovative Heart Pacemakers, Plus New Heart Pumps and Sensors to be Featured

News provided by

Leonhardt Ventures

Dec 16, 2013, 10:32 ET

SAN FRANCISCO, Dec. 16, 2013 /PRNewswire/ -- Leonhardt Ventures will showcase their portfolio healthcare innovations Wednesday, January 15th, 2014 5pm to 6:30pm @ PARISOMA 169 11th Street, San Francisco, CA 94103 - near JP Morgan Healthcare Conference. Please RSVP to Ms. Maddy Clemens, at [email protected].

Technologies to be showcased include:

Stem Cell Bra - The world's first stem cell recruiting (homing signal) bra designed to build new breast tissue from a women's own stem cells - www.stemcellbra.com.

MyoStim Pacers – http://www.myostimpacers.com - world's first heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.

Bioheart, Inc. – http://www.bioheartinc.com - Phase III leader in applying adult muscle stem cells to treat advanced heart failure since 1999. Only cell type known to grow new contractile muscle in the depths of scar tissue.

BioPace – biological pacemaker made entirely of living cells.

CoroStim – world's first vibrational energy emitting pacemaker designed to prevent plaque formation in high risk coronary arteries.

AortaCell unit of Stemergy - Stemergy is developing a lineup of non-invasive stem therapy directing devices - wherever signal is pointed stem cells are recruited and with a flip of a switch those recruited cells can be differentiated into the target organ tissue.

BioLeonhardt – http://www.bioleonhardt.com - combination electrical stimulation, stem cell pump and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure.

Cardiobridge – http://www.cardiobridge.com - Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI.

Procyrion Implantable Heart Pumps - www.procyrion.com - The Procyrion device consists of a small, continuous flow pump mounted within a self-expanding anchoring system.

HeartScore - www.heartscore.co – Composite scoring system of genetic, blood and artery scan test results that are loaded into the SecondBeat wearable wrist watch for a baseline score.

Stem Cell Pump - world's first implantable stem cell pump designed for controlled dose delivery of stem cells and selected growth factors over time to specific target organ locations.

LVSens – Implantable heart sensor.

CORE Manufacturing LLC - http://prn.to/169qrpw - http://core-manufacturing.com - cGMP contract manufacturing service.

The California Stock Xchange - The first social good impact stock exchange in the USA designed to also serve to finance life science companies in clinical trials (SEC registration pending) - www.calstockexchange.com - includes Cal-X Crowdfund Connect www.calxcrowdfund.com.

The Leonhardt Ventures' Cal-X Stars Business Accelerator, Inc. Scientific Advisory Board is made up of leading researchers - http://calxstars.com/scientific-advisory-board/.

Jane Reedy, the former VP of Clinical Affairs & Marketing at HeartWare and former Thoratec management member, and Suresh Gurunathan, Director of Engineering at Nanostim (first leadless pacemaker developed sold to St. Jude in October), have recently joined our advisory team.

Note - Bioheart will receive royalties and milestone payments from MyoStim Pacers, BioPace and BioLeonhardt.

Leonhardt Vineyards (www.leonhardtvineyards.com) gold medal winning wines will be served at the showcase event (which are available at 120 Trader Joe's stores in California).

Nov. 18th, 2013 - Leonhardt Ventures' Cal-X Stars Business Accelerator, Inc. announced a $15 million financing to accelerate its portfolio innovations forward under the new JOBS ACT Title II 506c exemption - http://prn.to/HVj1yx

About Leonhardt Ventures: Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions generating more than $3 billion in revenues. The Leonhardt team pioneered cardiovascular balloon catheters in the 80's, stent grafts and percutaneous heart valves in the 90's, stem cell therapies and cardiovascular genetic tests in the 2000s and electrical energy stem cell therapy devices, biological pacemakers and implantable pumps in the 2010's. Leonhardt Venture's started the Cal-X Stars Innovation and Business Accelerator in 2012 to guide forward cardiovascular and social good impact innovations over a 5 year period in preparation for a listing on the future California Stock Exchange (SEC registration pending).

Contact: Howard Leonhardt, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401, Office direct 310 310 2534, Email

This PR distribution was issued via PR Syndication.

RISK WARNING: The Cal-X Stars Business Accelerator, Inc. portfolio of innovations and startup companies are all un-proven early stage. The investment risk is very high and investors should be in position to lose all their investment without hurting their financial security. This 506c offering is limited to accredited investors only. Merriman Capital http://www.merrimanco.com/ has been hired as an advisory registered broker dealer for this offering. Any potential investor should review all risks published within our registered private placement memorandum.

RELATED LINKS
http://www.leonhardtventures.com